62st American Society of Hematology (ASH) Annual Meeting & Exposition

Oral and Poster Abstracts: Saturday, December 5th

793 Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice

Program: Oral and Poster Abstracts
Session: 113. Hemoglobinopathies, Excluding Thalassemia—New Genetic Approaches to Sickle Cell Disease: Poster I
Hematology Disease Topics & Pathways:
Anemias, sickle cell disease, Diseases, Hemoglobinopathies, Technology and Procedures
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Yuanbin Song, MD, Rana Gbyli, MS, Wei Liu, Ph.D., Yimeng Gao, PhD, Amisha Patel, MS, Xiaoying Fu, MD, Xiaman Wang, MD, Mina L. Xu, MD, Ashley Qin, Emanuela Bruscia, MD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Padmavathi Mamillapalli, BS, David Urbonas, David Gonzales, MS, Diane S. Krause, MD, PhD, Jonathan Alderman, PhD, Richard Flavell, PhD and Stephanie Halene, MD

927 Binding of FANCD2 to SRSF1 Splicing Factor Prevents Genomic Instability through R Loop Regulation

Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Poster I
Hematology Disease Topics & Pathways:
Diseases, Bone Marrow Failure, Biological Processes, DNA damage
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Manoj M Pillai, MD
1037 Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Adult, AML, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Study Population, Clinically relevant, Myeloid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

1151 A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, T-Cell Lymphoma, immunotherapy,
Lymphoid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Francine M. Foss, MD

1167 Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
Adult, Biological, antibodies, Therapies, Study Population, Clinically relevant
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Megan Lee, BS, Molly Schiffer, PharmD, Iris Isufi, MD, Scott F. Huntington, MD, MPH, Mina L. Xu, MD, Stuart Seropian, MD, Lohith Gowda, MD, Shalin K. Kothari, MD, Michael Girardi, MD, PhD and Francine M. Foss, MD
1230 Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
- Diseases, CMML, MDS, Biological Processes, epigenetics, Myeloid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

1294 The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
Hematology Disease Topics & Pathways:
- AML, Biological, antibodies, Diseases, Therapies, MDS, Myeloid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

1520 Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Hematology Disease Topics & Pathways:
- Diseases, Lymphoid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Francine M. Foss, MD
1528 Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome – a Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 732. Clinical Allogeneic Transplantation: Results: Poster I
Hematology Disease Topics & Pathways:
Biological, AML, Non-Biological, bone marrow, Diseases, Therapies, chemotherapy, MDS, Clinically relevant, Myeloid Malignancies, transplantation
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

1572 The Impact of COVID-19 on Hematology-Oncology Fellowship Programs: Program Director Perspectives

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster I
Hematology Disease Topics & Pathways:
Coronaviruses, SARS-CoV-2/COVID-19
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Alfred Ian Lee, MD, PhD

1590 Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Scott F. Huntington, MD, MPH

1594 Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster I
1618 The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents

Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I
Hematology Disease Topics & Pathways:
Adult, Diseases, Therapies, MDS, Study Population, Myeloid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

780 Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but its Ablation Doesn’t Improve Erythroid Maturation

Program: Oral and Poster Abstracts
Type: Poster
Session: 112. Thalassemia and Globin Gene Regulation: Poster I
Hematology Disease Topics & Pathways:
Adult, Anemias, Biological, Coronaviruses, SARS-CoV-2/COVID-19, sickle cell disease, survivorship, Diseases, drug-drug interaction, Combinations, thalassemia, Therapies, red blood cells, Biological Processes, Hemoglobinopathies, gene therapy, Young Adult, Cell Lineage, epigenetics, erythropoiesis, Study Population, Clinically relevant, Quality Improvement
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Vijay Menon, PhD

1669 Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia
41 Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Biological, Diseases, Therapies, T-Cell Lymphoma, Lymphoid Malignancies, Study Population, Clinically relevant, transplantation
Saturday, December 5, 2020: 8:00 AM
Francine M. Foss, MD

135 High Doses of Targeted Radiation with Anti-CD45 Iodine (\(^{131}\)I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I
Hematology Disease Topics & Pathways:
82 Novel Fluorescent Timer Tool Enables Characterization of Erythropoietic Differentiation Based on Differential Cell Cycling Speeds

Program: Oral and Poster Abstracts
Type: Oral
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Mechanisms, Diagnosis and Treatment of Inherited Hematology Disease Topics & Pathways:
- Adult, Anemias, HSCs, Biological, Diseases, Animal models, aplastic anemia, cell division, iPSCs, cell regulation, Therapies, Genetic Disorders, red blood cells, blood banking,
- Biological Processes, Technology and Procedures, cell expansion, gene therapy, Cell Lineage, gene editing, Study Population, erythropoiesis, genomics, Clinically relevant, hematopoiesis, imaging, flow cytometry, stem cells, NGS, molecular interactions, pathogenesis, pathways, proteomics

Saturday, December 5, 2020: 9:30 AM
Anna Eastman, PhD

101 Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience

Program: Oral and Poster Abstracts
Type: Oral
Session: 401 Basic Science and Clinical Practice in Blood Transfusion: COVID-19 Convalescent Plasma, Antigen Typing and the Prothrombin Complex II
Hematology Disease Topics & Pathways:
- Coronaviruses, SARS-CoV-2/COVID-19, viral, Biological, antibodies, Adult, Diseases, Therapies, blood banking, Technology and Procedures, Infectious Diseases, Study Population, Clinically relevant, transfusion
126 A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter’s Transformation and De Novo Diffuse Large B-Cell Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. CLL: Therapy, excluding Transplantation I
Hematology Disease Topics & Pathways:
Adult, Lymphoma (any), Diseases, Combinations, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Lymphoid Malignancies, Study Population, Clinically relevant

139 Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I
Hematology Disease Topics & Pathways:
Biological, sickle cell disease, Diseases, Therapies, Hemoglobinopathies, transplantation, stem cells
213 Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 906-Outcomes Research—Malignant Conditions (Myeloid Disease): Real World Management And Outcome
Hematology Disease Topics & Pathways: Therapies, Clinically relevant
Saturday, December 5, 2020: 12:00 PM
Channel 4 (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

193 Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ($^{131}$I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II
Saturday, December 5, 2020: 1:00 PM
Stuart Seropian, MD

262 Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Program: Oral and Poster Abstracts
Type: Oral
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases
Hematology Disease Topics & Pathways: therapy sequence, Combinations, Therapies, Clinically relevant
Saturday, December 5, 2020: 2:30 PM
Channel 14 (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS
308 Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Program: Oral and Poster Abstracts
Type: Oral
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease) I
Hematology Disease Topics & Pathways:
Diseases, Combinations, Elderly, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement
Saturday, December 5, 2020: 2:30 PM
Jessica B Long, MPH, Natalia Neparidze, MD, Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Nikolai A. Podoltsev, MD, PhD, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS and Scott F. Huntington, MD, MPH

Scientific Sessions: Sunday, December 6
12:00-12:45
Carrie Lucas, MD
“Human PI3K Mutations: Immunodeficiency and Malignancy”.

Oral and Poster Abstracts: Sunday, December 6th

1909 Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Biological, AML, Diseases, Therapies, immunotherapy, Myeloid Malignancies, Clinically relevant
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS
1943 Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation
Hematology Disease Topics & Pathways:
Leukemia, Adult, Diseases, Non-Biological, Therapies, Technology and Procedures,
Lymphoid Malignancies, Study Population, genetic profiling
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

1954 Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation:
Poster II
Hematology Disease Topics & Pathways:
AML, Biological, Diseases, Therapies, enzyme inhibitors, Myeloid Malignancies, Clinically relevant
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

2148 Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II
Hematology Disease Topics & Pathways:
Biological, Adult, Diseases, CML, Therapies, checkpoint inhibitors, Study Population,
Myeloid Malignancies, Clinically relevant, TKI
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)

Amer M. Zeidan, MBBS, MHS

**2199 Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study**

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Hematology Disease Topics & Pathways:
Adult, Diseases, MDS, Study Population, Myeloid Malignancies, Clinically relevant
Sunday, December 6, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)

Amer M. Zeidan, MBBS, MHS

**2473 Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment**

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster II
Hematology Disease Topics & Pathways:
Quality Improvement
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Alfred Ian Lee, MD, PhD

**2474 Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study**

Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster II
Hematology Disease Topics & Pathways:
survivorship, Diseases, Elderly, MPN, Study Population, Myeloid Malignancies, Clinically relevant, Quality Improvement
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Shelby Meckstroth, Rong Wang, PhD, Xiaomei Ma, PhD and Nikolai A. Podoltsev, MD, PhD
2522 Under-Use of Hypomethylating Agents in Patients with Higher-Risk Myelodysplastic Syndrome in the United States: A Large Population-Based Analysis  
Program: Oral and Poster Abstracts  
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster II  
Sunday, December 6, 2020, 7:00 AM-3:30 PM  
Poster Hall (Virtual Meeting)  
Amer M. Zeidan, MBBS, MHS

2545 Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)  
Program: Oral and Poster Abstracts  
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II  
Hematology Disease Topics & Pathways:  
Leukemia, Biological, antibodies, Adult, Diseases, CLL, Therapies, Adverse Events, Lymphoid Malignancies  
Sunday, December 6, 2020, 7:00 AM-3:30 PM  
Scott F. Huntington, MD, MPH

326 Cell Cycle Regulates Phosphorylation of RUNX1 to Modulate Megakaryocyte-Enthroid Progenitor Fate Specification  
Program: Oral and Poster Abstracts  
Type: Oral  
Session: 502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis and Cell Cycle Regulation: Molecular regulation of cell fate and regeneration  
Hematology Disease Topics & Pathways:  
HSCs, Adult, AML, cell division, Animal models, Diseases, cell regulation, Bone Marrow Failure, platelets, cellular interactions, Genetic Disorders, MDS, red blood cells, white blood cells, Biological Processes, Technology and Procedures, cell expansion, immune cells, Cell Lineage, Xenograft models, epigenetics, gene editing, Study Population, erythropoiesis, genomics, Myeloid Malignancies, hematopoiesis, flow cytometry,
inflammation, integrative -omics, NGS, microenvironment, RNA sequencing, molecular interactions, pathways, signal transduction

Sunday, December 6, 2020, 9:30 AM – 11:00 AM

Yi-Chien Lu, PhD, Vanessa M Scanlon, PhD, Juliana Xavier-Ferrucio, PhD

360 Creating a Variant Database for the American Society of Hematology by Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Program: Oral and Poster Abstracts
Type: Oral
Session: 803. Emerging Diagnostic Tools and Techniques I
Hematology Disease Topics & Pathways:
AML, Biological, antibodies, Adult, ALL, apoptosis, Leukemia, CML, Diseases, Non-Biological, CMML, Therapies, Combinations, MDS, B-Cell Lymphoma, MPN, enzyme inhibitors, Biological Processes, white blood cells, T-Cell Lymphoma, Technology and Procedures, Plasma Cell Disorders, Cell Lineage, Lymphoid Malignancies, Study Population, Myeloid Malignancies, Clinically relevant, genetic profiling, genomics, Quality Improvement, flow cytometry, molecular testing, NGS
Sunday, December 6, 2020, 9:30 AM – 11:00 AM
Alexa J. Siddon, MD

334 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches
Hematology Disease Topics & Pathways:
AML, Biological, antibodies, Adult, Leukemia, Diseases, Combinations, Therapies, MDS, Study Population, Myeloid Malignancies, Clinically relevant, TKI, stem cells
Sunday, December 6, 2020, 9:30 AM – 11:00 AM
Nikolai A. Podoltsev, MD, PhD
427 Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura

Program: Oral and Poster Abstracts
Type: Oral
Session: 901. Health Services Research—Non-Malignant Conditions II
Hematology Disease Topics & Pathways:
Bleeding and clotting, Diseases, Thrombosis, Platelet Disorders, TTP, VWD
Sunday, December 6, 2020: 12:45 PM
George Goshua, MD, Jeanne E. Hendrickson, MD, Christopher A. Tormey, MD, Alfred Ian Lee, MD, PhD

410 High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Program: Oral and Poster Abstracts
Type: Oral
Session: 636. Myelodysplastic Syndromes — Basic and Translational Studies
Hematology Disease Topics & Pathways:
Diseases, Biological Processes, Myeloid Malignancies, integrative -omics
Sunday, December 6, 2020: 1:00 PM
Giulia Biancon, PhD, Poorval Joshi, PhD, Torben Hunck, Josh Zimmer, MS, Yimeng Gao, PhD, Martin Machyna, PhD, Valentina Botti, PhD, Ashley Qin, Nils Neuenkirchen, PhD, Ashley Taylor, Rana Gbyli, MS, Amisha Patel, MS, Anastasia Ardasheva, BS, Xiaoying Fu, MD, Haifan Lin, PhD, Matthew D Simon, PhD, Karla M Neugebauer, PhD, Toma Tebaldi, PhD and Stephanie Halene, MD

478 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: PCNSL
Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas

Hematology Disease Topics & Pathways:
- antibodies, Adult, Diseases, Non-Biological, Therapies, Combinations, CNS Lymphoma, chemotherapy, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies,
- Study Population, Clinically relevant

Sunday, December 6, 2020: 2:30 PM

Scott F. Huntington, MD, MPH

Scientific Sessions: Monday, December 7
9:00-9:30
Martin Kriegel, MD, PhD
Microbiota and Thrombosis

Oral and Poster Abstracts: Monday, December 7th

605 Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases:
Molecular pharmacology and drug resistance mechanisms in lymphoproliferative disorders

Program: Oral and Poster Abstracts
Type: Oral

Hematology Disease Topics & Pathways:
- antibodies, Biological, ALL, AML, apoptosis, Leukemia, Non-Biological, CLL, Diseases, drug-drug interaction, Lymphoma (any), CAR-Ts, Combinations, Therapies, Hodgkin Lymphoma, Mantle Cell Lymphoma, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DNA damage, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, pharmacology, Quality Improvement, TKI, integrative -omics, molecular testing, metabolomics, molecular interactions, pathways, proteomics, signal transduction

Monday, December 7, 2020, 7:00 AM-8:30 AM

Moderator: Scott F. Huntington, MD, MPH
2690 VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study

Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster III
Hematology Disease Topics & Pathways:
SARS-CoV-2/COVID-19, Coronaviruses, Adult, Diseases, Bleeding and clotting, Study
Population, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Daria V Madeeva, MD, Jana Christian, MD, George Goshua, MD, Hyung J. Chun, MD, Alfred Ian Lee, MD, PhD and Alexander B Pine, MD, PhD

2724 Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes

Program: Oral and Poster Abstracts
Session: 401. Basic Science and Clinical Practice in Blood Transfusion: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Rory M. Shallis, MD, Amer M. Zeidan, MD

2809 Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
AML, Biological, Diseases, Therapies, Combinations, immunotherapy, Myeloid Malignancies, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS
2825 Trial in Progress: Glad-AML – a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
AML, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Study Population, Myeloid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM
Rory M. Shallis, MD, Nikolai A. Podoltsev, MD, PhD, Thomas Prebet, MD, PhD and Amer M. Zeidan, MBBS, MHS

2826 Streamline – Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
AML, Diseases, Myeloid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

2844 Exploratory Analysis of the Efficacy and Safety of CPX-351 Versus 7+3 By European Leukemianet (ELN) 2017 Risk Groups in a Phase 3 Study of Older Adults with High-Risk/Secondary Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways:
AML, Diseases, Non-Biological, Therapies, Elderly, chemotherapy, Study Population, Myeloid Malignancies, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Thomas Prebet, MD, PhD
2942 Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Therapies, Combinations, Study Population, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Iris Isufi, MD

3045 Outcomes of Patients (pts) with Primary CNS Lymphoma (PCNSL) Treated with the De Angelis-Lite Protocol (Modified DeAngelis Protocol with Omission of Consolidative Radiotherapy): The Roswell Park Comprehensive Cancer Center (RPCCC) Experience

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Shalin K. Kothari, MD

3109 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS
3111 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
Diseases, MDS, MPN, Clinically relevant, Myeloid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM
Poster Hall (Virtual Meeting)
Amer M. Zeidan, MBBS, MHS

3164 Hematologic Malignancies and Monoclonal Gammopathy of Undetermined Significance (MGUS) in Gaucher Disease Type 1 Patients in the International Cooperative Gaucher Group Gaucher Registry

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III
Hematology Disease Topics & Pathways:
multiple myeloma, Adult, Biological, Diseases, Non-Biological, Therapies, Combinations, biopsy, Biological Processes, enzyme inhibitors, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, imaging, flow cytometry, pathogenesis
Monday, December 7, 2020, 7:00 AM-3:30 PM
Pramod K. Mistry, MD, PhD, FRCP

3173 Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III
Hematology Disease Topics & Pathways:
multiple myeloma, Adult, Biological, Diseases, Non-Biological, Therapies, Combinations, biopsy, Biological Processes, enzyme inhibitors, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, imaging, flow cytometry, pathogenesis
Monday, December 7, 2020, 7:00 AM-3:30 PM
Sabrina L. Browning, MD, Terri L. Parker, MD, Noffer Bar, MD, Tara Anderson, PA, Stuart Seropian, MD, Alfred Ian Lee, MD, PhD, Thomas Prebet, MD, PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD, PhD, Andrew Haims, MD and Natalia Neparidze, MD

2908 Genetic Determinants of Blood Cell Traits Play a Role in Susceptibility to Acute Lymphoblastic Leukemia

Program: Oral and Poster Abstracts
Type: Poster
Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
Hematology Disease Topics & Pathways:
Adult, ALL, AML, Leukemia, Diseases, Therapies, MDS, Pediatric, Biological Processes, white blood cells, Technology and Procedures, Young Adult, cytogenetics, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, genetic profiling, genomics, Myeloid Malignancies, molecular testing, NGS, RNA sequencing

Monday, December 7, 2020, 7:00 AM-3:30 PM
Andrew DeWan, PhD, Xiaomei Ma, PhD

3439 Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost

Program: Oral and Poster Abstracts
Type: Poster
Session: 903. Health Services Research – Malignant Conditions (Myeloid Disease): Poster III
Hematology Disease Topics & Pathways:
Adult, AML, Biological, Coronaviruses, Leukemia, multiple myeloma, SARS-CoV-2/COVID-19, therapy sequence, CML, Diseases, Lymphoma (any), Non-Biological, Bone Marrow Failure, Combinations, Elderly, Therapies, chemotherapy, Non-Hodgkin Lymphoma, Biological Processes, DLBCL, MPN, Polycythemia vera, Technology and Procedures,
immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement, TKI, molecular testing, NGS
Monday, December 7, 2020, 7:00 AM-3:30 PM
Savanah D. Gisriel, MD, MPH, Henry M. Rinder, MD, Alexa J. Siddon, MD

### 3391 Factors Associated with Burnout Among Hematology & Oncology Physicians

Program: Oral and Poster Abstracts  
Session: 901. Health Services Research—Non-Malignant Conditions: Poster III  
Hematology Disease Topics & Pathways: Quality Improvement  
Monday, December 7, 2020, 7:00 AM-3:30 PM  
Alfred Ian Lee, MD, PhD

### 543 Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Program: Oral and Poster Abstracts  
Type: Oral  
Session: 642. CLL: Therapy, excluding Transplantation II  
Hematology Disease Topics & Pathways: Biological, antibodies, Diseases, CLL, Lymphoma (any), Non-Biological, Therapies, Combinations, Lymphoid Malignancies  
Monday, December 7, 2020: 7:15 AM  
Scott F. Huntington, MD, MPH

### 3443 Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Program: Oral and Poster Abstracts  
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Hematology Disease Topics & Pathways:
CML, Non-Biological, Diseases, Elderly, Therapies, chemotherapy, Study Population, Myeloid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM
Rory M. Shallis, MD, Rong Wang, PhD, Jan Philipp Bewersdorf, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD, MPH, Amy J Davidoff, PhD, MS, Xiaomei Ma, PhD and Nikolai A. Podoltsev, MD, PhD

620 Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Program: Oral and Poster Abstracts
Type: Oral
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease):
Treatment and Publication Patterns in Myeloid Malignancies
Hematology Disease Topics & Pathways:
Non-Biological, Diseases, CML, Therapies, Elderly, chemotherapy, Study Population, Myeloid Malignancies
Monday, December 7, 2020: 9:00 AM
Rong Wang, PhD, Rory M. Shallis, MD, Jan Philipp Bewersdorf, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD, MPH, Xiaomei Ma, PhD and Nikolai A. Podoltsev, MD, PhD

579 Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis

Program: Oral and Poster Abstracts
Type: Oral
Session: 332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications
Hematology Disease Topics & Pathways:
SARS-CoV-2/COVID-19, Coronaviruses, Clinically relevant, Thrombotic Disorders
Monday, December 7, 2020: 9:45 AM
635 Myeloproliferative Syndromes: Basic Science

Program: Oral and Poster Abstracts
Type: Oral
Session: 713. Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Hematology Disease Topics & Pathways:
apoptosis, Biological, HSCs, Animal models, cell division, Diseases, Non-Biological, Therapies, cellular interactions, Biological Processes, DNA damage, MPN, Polycytemia vera, Technology and Procedures, Cell Lineage, epigenetics, immunotherapy, thrombocytemia, Study Population, Clinically relevant, Myeloid Malignancies, hematopoiesis, flow cytometry, inflammation, molecular interactions, pathogenesis, pathways, signal transduction

Monday, December 7, 2020: 1:30 PM – 3:00 PM

Rong Fan, PhD

743 Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease) II
Hematology Disease Topics & Pathways:
Diseases, Lymphoma (any), Therapies, Combinations, Elderly, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement

Monday, December 7, 2020: 1:45 PM

Mengyang Di, MD
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Plasma Cell Disorders, Lymphoid Malignancies
Monday, December 7, 2020: 2:30 PM
Terri L. Parker, MD